CFH variants affect structural and functional brain changes and genetic risk of Alzheimer's Disease. Neuropsychopharmacology, 2016, 41(4): 1034-45 Title: CFH variants affect structural and functional brain changes and genetic risk of Alzheimer's Disease. Author: Zhang DF, Li J, Wu H, Cui Y, Bi R, Zhou HJ, Wang HZ, Zhang C, Wang D; Alzheimer's Disease Neuroimaging Initiative (ADNI), Kong QP, Li T, Fang Y, Jiang T, Yao YG Publication Name: Neuropsychopharmacology Pub Year: 2016 Volume: 41 Issue: 4 Page Number: 1034-45 IF: 6.399 Abstract: The immune response is highly active in Alzheimer's disease (AD). Identification of genetic risk contributed by immune genes to AD may provide essential insight for the prognosis, diagnosis, and treatment of this neurodegenerative disease. In this study, we performed a genetic screening for AD-related top immune genes identified in Europeans in a Chinese cohort, followed by a multiple-stage study focusing on Complement Factor H (CFH) gene. Effects of the risk SNPs on AD-related neuroimaging endophenotypes were evaluated through magnetic resonance imaging scan, and the effects on AD cerebrospinal fluid biomarkers (CSF) and CFHexpression changes were measured in aged and AD brain tissues and AD cellular models. Our results showed that the AD-associated top immune genes reported in Europeans (CR1, CD33, CLU, and TREML2) have weak effects in Chinese, whereas CFH showed strong effects. In particular, rs1061170 (P(meta)=5.0 × 10(-4)) and rs800292 (P(meta)=1.3 × 10(-5)) showed robust associations with AD, which were confirmed in multiple world-wide sample sets (4317 cases and 16 795 controls). Rs1061170 (P=2.5 × 10(-3)) and rs800292 (P=4.7 × 10(-4)) risk-allele carriers have an increased entorhinal thickness in their young age and a higher atrophy rate as the disease progresses. Rs800292 risk-allele carriers have higher CSF tau and Aβ levels and severe cognitive decline. CFHexpression level, which was affected by the risk-alleles, was increased in AD brains and cellular models. These comprehensive analyses suggested that CFH is an important immune factor in AD and affects multiple pathological changes in early life and duringdisease progress. |